Literature DB >> 26078272

H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem.

Adam K Wheatley1, James R R Whittle1, Daniel Lingwood2, Masaru Kanekiyo1, Hadi M Yassine1, Steven S Ma1, Sandeep R Narpala1, Madhu S Prabhakaran1, Rodrigo A Matus-Nicodemos1, Robert T Bailer1, Gary J Nabel3, Barney S Graham1, Julie E Ledgerwood1, Richard A Koup1, Adrian B McDermott4.   

Abstract

Because of significant viral diversity, vaccines that elicit durable and broad protection against influenza have been elusive. Recent research has focused on the potential of highly conserved regions of the viral hemagglutinin (HA) as targets for broadly neutralizing Ab responses. Abs that bind the highly conserved stem or stalk of HA can be elicited by vaccination in humans and animal models and neutralize diverse influenza strains. However, the frequency and phenotype of HA stem-specific B cells in vivo remain unclear. In this article, we characterize HA stem-specific B cell responses following H5N1 vaccination and describe the re-expansion of a pre-existing population of memory B cells specific for stem epitopes. This population uses primarily, but not exclusively, IGHV1-69-based Igs for HA recognition. However, within some subjects, allelic polymorphism at the ighv1-69 locus can limit IGHV1-69 immunodominance and may reduce circulating frequencies of stem-reactive B cells in vivo. The accurate definition of allelic selection, recombination requirements, and ontogeny of neutralizing Ab responses to influenza will aid rational influenza vaccine design.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26078272      PMCID: PMC4491024          DOI: 10.4049/jimmunol.1402835

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Molecular characterization of the VH1-specific variable region determinants recognized by anti-idiotypic monoclonal antibodies G6 and G8.

Authors:  K N Potter; Y Li; R A Mageed; R Jefferis; J D Capra
Journal:  Scand J Immunol       Date:  1999-07       Impact factor: 3.487

2.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

3.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

4.  Rapid development of broadly influenza neutralizing antibodies through redundant mutations.

Authors:  Leontios Pappas; Mathilde Foglierini; Luca Piccoli; Nicole L Kallewaard; Filippo Turrini; Chiara Silacci; Blanca Fernandez-Rodriguez; Gloria Agatic; Isabella Giacchetto-Sasselli; Gabriele Pellicciotta; Federica Sallusto; Qing Zhu; Elisa Vicenzi; Davide Corti; Antonio Lanzavecchia
Journal:  Nature       Date:  2014-10-05       Impact factor: 49.962

5.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

6.  Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis.

Authors:  Matthew S Miller; Thomas J Gardner; Florian Krammer; Lauren C Aguado; Domenico Tortorella; Christopher F Basler; Peter Palese
Journal:  Sci Transl Med       Date:  2013-08-14       Impact factor: 17.956

7.  Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.

Authors:  Ali H Ellebedy; Florian Krammer; Gui-Mei Li; Matthew S Miller; Christopher Chiu; Jens Wrammert; Cathy Y Chang; Carl W Davis; Megan McCausland; Rivka Elbein; Srilatha Edupuganti; Paul Spearman; Sarah F Andrews; Patrick C Wilson; Adolfo García-Sastre; Mark J Mulligan; Aneesh K Mehta; Peter Palese; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-25       Impact factor: 11.205

8.  H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.

Authors:  M Anthony Moody; Ruijun Zhang; Emmanuel B Walter; Christopher W Woods; Geoffrey S Ginsburg; Micah T McClain; Thomas N Denny; Xi Chen; Supriya Munshaw; Dawn J Marshall; John F Whitesides; Mark S Drinker; Joshua D Amos; Thaddeus C Gurley; Joshua A Eudailey; Andrew Foulger; Katherine R DeRosa; Robert Parks; R Ryan Meyerhoff; Jae-Sung Yu; Daniel M Kozink; Brice E Barefoot; Elizabeth A Ramsburg; Surender Khurana; Hana Golding; Nathan A Vandergrift; S Munir Alam; Georgia D Tomaras; Thomas B Kepler; Garnett Kelsoe; Hua-Xin Liao; Barton F Haynes
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

9.  Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses.

Authors:  Yuval Avnir; Aimee S Tallarico; Quan Zhu; Andrew S Bennett; Gene Connelly; Jared Sheehan; Jianhua Sui; Amr Fahmy; Chiung-yu Huang; Greg Cadwell; Laurie A Bankston; Andrew T McGuire; Leonidas Stamatatos; Gerhard Wagner; Robert C Liddington; Wayne A Marasco
Journal:  PLoS Pathog       Date:  2014-05-01       Impact factor: 6.823

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  50 in total

1.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

2.  Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Authors:  Anne B Kristensen; William N Lay; Fernanda Ana-Sosa-Batiz; Hillary A Vanderven; Vijaya Madhavi; Karen L Laurie; Louise Carolan; Bruce D Wines; Mark Hogarth; Adam K Wheatley; Stephen J Kent
Journal:  J Virol       Date:  2016-05-27       Impact factor: 5.103

3.  Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem.

Authors:  Elene Clemens; Davide Angeletti; Beth C Holbrook; Masaru Kanekiyo; Matthew J Jorgensen; Barney S Graham; Jonathan Yewdell; Martha A Alexander-Miller
Journal:  JCI Insight       Date:  2020-03-12

Review 4.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

Review 5.  Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.

Authors:  Sarah F Andrews; Barney S Graham; John R Mascola; Adrian B McDermott
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

6.  Germline-Encoded Affinity for Cognate Antigen Enables Vaccine Amplification of a Human Broadly Neutralizing Response against Influenza Virus.

Authors:  Maya Sangesland; Larance Ronsard; Samuel W Kazer; Julia Bals; Seyhan Boyoglu-Barnum; Ashraf S Yousif; Ralston Barnes; Jared Feldman; Maricel Quirindongo-Crespo; Patrick M McTamney; Daniel Rohrer; Nils Lonberg; Bryce Chackerian; Barney S Graham; Masaru Kanekiyo; Alex K Shalek; Daniel Lingwood
Journal:  Immunity       Date:  2019-09-25       Impact factor: 31.745

7.  Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.

Authors:  Sinthujan Jegaskanda; Sarah F Andrews; Adam K Wheatley; Jonathan W Yewdell; Adrian B McDermott; Kanta Subbarao
Journal:  JCI Insight       Date:  2019-11-14

Review 8.  B-cell responses to HIV infection.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

9.  Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses.

Authors:  M Gordon Joyce; Adam K Wheatley; Paul V Thomas; Gwo-Yu Chuang; Cinque Soto; Robert T Bailer; Aliaksandr Druz; Ivelin S Georgiev; Rebecca A Gillespie; Masaru Kanekiyo; Wing-Pui Kong; Kwanyee Leung; Sandeep N Narpala; Madhu S Prabhakaran; Eun Sung Yang; Baoshan Zhang; Yi Zhang; Mangaiarkarasi Asokan; Jeffrey C Boyington; Tatsiana Bylund; Sam Darko; Christopher R Lees; Amy Ransier; Chen-Hsiang Shen; Lingshu Wang; James R Whittle; Xueling Wu; Hadi M Yassine; Celia Santos; Yumiko Matsuoka; Yaroslav Tsybovsky; Ulrich Baxa; James C Mullikin; Kanta Subbarao; Daniel C Douek; Barney S Graham; Richard A Koup; Julie E Ledgerwood; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola; Adrian B McDermott
Journal:  Cell       Date:  2016-07-21       Impact factor: 41.582

10.  In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates.

Authors:  Grant C Weaver; Rina F Villar; Masaru Kanekiyo; Gary J Nabel; John R Mascola; Daniel Lingwood
Journal:  Nat Protoc       Date:  2016-01-07       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.